PaulKPaikMD

PubMed

• 2 citations
  A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
  Noura J Choudhury, W Victoria Lai, Alex Makhnin, Glenn Heller, Juliana Eng
  Clinical Cancer Research. 2024-09-03
• Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis.
  Zachary R Moore, Xiaojing Huang, Stephanie Lobaugh, Zhigang Zhang, Phillip Wong
  Radiotherapy and Oncology. 2024-07-01
• 4 citations
  Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
  Jia Luo, Michelle Sanchez, Elinton Lee, Hans Hertzler, Nhi Luong
  Journal of Thoracic Oncology. 2024-05-01

Journal Articles

• Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations  
  Paul K Paik, Xiuning Le, The New England Journal of Medicine
• PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  
  G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
• YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics  
  Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

• Phase II study of tepotinib in NSCLC patients with METex14 mutations. 
  2019 ASCO Annual Meeting - 6/1/2019
• Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228. 
  2019 ASCO Annual Meeting - 6/1/2019
• Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018